ST. JOSEPH, Mich., Jan. 12 -- GeneGo, Inc., the leading systems biology tools company, announced today they have been awarded a $336K Phase I SBIR grant from the NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES for creating a novel type of predictive signatures for drug resistance. Under this project GeneGo will develop "regulation signatures" which should overcome many shortcomings of existing methods of molecular diagnostics. For this work GeneGo will utilize its extensive, manually-curated database of signaling interactions and recently developed algorithms for identifying key proteins in signaling networks. The work will be performed in collaboration with the Van Andel Institute for Translational Medicine.
"What we propose here is the novel concept of using inferred activity of key signaling proteins for building predictive models. Our early results indicate that such models should be significantly more robust than currently available diagnostic applications which are based directly on gene or protein levels. We are very excited about the opportunity provided by NIH support to further develop and validate this approach. If successful, the methodology could be replicated for developing predictive models for sensitivity to a broad range of targeted therapies, leading to a number of diagnostic applications such as specialized molecular tests, systems for formulating combination therapies and procedures for selecting patient cohorts for clinical trials," said Andrej Bugrim, GeneGo COO and PI on the grant.
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.0™, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.0™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
SOURCE GeneGo, Inc.
Advertisement
"What we propose here is the novel concept of using inferred activity of key signaling proteins for building predictive models. Our early results indicate that such models should be significantly more robust than currently available diagnostic applications which are based directly on gene or protein levels. We are very excited about the opportunity provided by NIH support to further develop and validate this approach. If successful, the methodology could be replicated for developing predictive models for sensitivity to a broad range of targeted therapies, leading to a number of diagnostic applications such as specialized molecular tests, systems for formulating combination therapies and procedures for selecting patient cohorts for clinical trials," said Andrej Bugrim, GeneGo COO and PI on the grant.
Advertisement
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.0™, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.0™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
SOURCE GeneGo, Inc.
